Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 14–15
HOS-115560 · Präparat HOS-094307
14
Description of selected adverse reactions
Gallstones and related biliary disorders were reported in about 2% of patients. Elevations of liver
transaminases were reported as an adverse reaction in 2% of patients. Elevations of transaminases
greater than 10 times the upper limit of the normal range, suggestive of hepatitis, were uncommon
(0.3%). During post-marketing experience, hepatic failure, sometimes fatal, has been reported with
deferasirox (see section 4.4). There have been post-marketing reports of metabolic acidosis. The
majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea,
or conditions where acid-base imbalance is a known complication (see section 4.4). Cases of serious
acute pancreatitis were observed without documented underlying biliary conditions. As with other iron
chelator treatment, high-frequency hearing loss and lenticular opacities (early cataracts) have been
uncommonly observed in patients treated with deferasirox (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage ac19c9a6c666b0f62f12bcd217a90839598372e968944b29af59247555c0cb56 · Zeichen 4785–5801 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-115561 · Präparat HOS-094307
Creatinine clearance in transfusional iron overload
In a retrospective meta-analysis of 2 102 adult and paediatric beta-thalassaemia patients with
transfusional iron overload treated with deferasirox dispersible tablets in two randomised and four
open label studies of up to five years’ duration, a mean creatinine clearance decrease of 13.2% in adult
patients (95% CI: -14.4% to -12.1%; n=935) and 9.9% (95% CI: -11.1% to -8.6%; n=1 142) in
paediatric patients was observed during the first year of treatment. In 250 patients who were followed
for up to five years, no further decrease in mean creatinine clearance levels was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 5a97dbf5702e7bdc9f6e639cd5e6ba9650874f44e2f60c31d7d8ca034e692c8b · Zeichen 5803–6439 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-115562 · Präparat HOS-094307
Clinical study in patients with non-transfusion-dependent thalassaemia syndromes
In a 1-year study in patients with non-transfusion-dependent thalassaemia syndromes and iron
overload (dispersible tablets at a dose of 10 mg/kg/day), diarrhoea (9.1%), rash (9.1%), and nausea
(7.3%) were the most frequent study drug-related adverse events. Abnormal serum creatinine and
creatinine clearance values were reported in 5.5% and 1.8% of patients, respectively. Elevations of
liver transaminases greater than 2 times the baseline and 5 times the upper limit of normal were
reported in 1.8% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 383be065a8d9afd8c4993904e06322e3af97fdf4985dd74fff1d36adddde8b8b · Zeichen 6441–7036 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-115563 · Präparat HOS-094307
Paediatric population
In three clinical studies, growth and sexual development of paediatric patients treated with deferasirox
for up to 5 years were not affected (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage c2dec7628871ee0855c50e319162a80b45ce2110656a55a48c2373d885021787 · Zeichen 7038–7219 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-115564 · Präparat HOS-094307
Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years than in older patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 9bd3742414ca9dead248728436cd50a01deb6dabe7981bd2bee444be03d01f16 · Zeichen 7221–7321 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-115565 · Präparat HOS-094307
Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia treated
with deferasirox. In post-marketing reports, a high proportion of cases of metabolic acidosis occurred
in children in the context of Fanconi syndrome.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage b624bee1a82c9e88370024b6842449a21bb2ee74c789ceca877fb11fc22dc6ca · Zeichen 7323–7575 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-115566 · Präparat HOS-094307
Acute pancreatitis has been reported, particularly in children and adolescents.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage c2d7f7a67ff70df455adabc50fe2f82f4f0936a294cc611db82b98b4388bd6a0 · Zeichen 7577–7656 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-115567 · Präparat HOS-094307
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 7658–8013 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 33
HOS-115581 · Präparat HOS-094307
Summary of the safety profile
The most frequent reactions reported during chronic treatment in clinical studies conducted with
deferasirox dispersible tablets in adult and paediatric patients include gastrointestinal disturbances
(mainly nausea, vomiting, diarrhoea or abdominal pain) and skin rash. Diarrhoea is reported more
commonly in paediatric patients aged 2 to 5 years and in the elderly. These reactions are dose-
dependent, mostly mild to moderate, generally transient and mostly resolve even if treatment is
continued.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage ba75ec93136f28aa52ce0ddc3af0db84b6dc08f0ba3250cf8de82eccd29f5d57 · Zeichen 0–529 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 33
HOS-115582 · Präparat HOS-094307
During clinical studies dose-dependent increases in serum creatinine occurred in about 36% of
patients, though most remained within the normal range. Decreases in mean creatinine clearance have
been observed in both paediatric and adult patients with beta-thalassemia and iron overload during the
first year of treatment, but there is evidence that this does not decrease further in subsequent years of
treatment. Elevations of liver transaminases have been reported. Safety monitoring schedules for renal
and liver parameters are recommended. Auditory (decreased hearing) and ocular (lens opacities)
disturbances are uncommon, and yearly examinations are also recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage f4b354d007076fb1e0512415d18c704678f13d12d69dd1791fc6992891173a78 · Zeichen 531–1222 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 33
HOS-115583 · Präparat HOS-094307
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic
epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS)
have been reported with the use of EXJADE (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 28bdc5103398dd2ab1ca027f8b5e8cbb4da1dca6ca9a662b336a79e98d362b7e · Zeichen 1224–1469 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 33
HOS-115584 · Präparat HOS-094307
Tabulated list of adverse reactions
Adverse reactions are ranked below using the following convention: very common (≥1/10); common
(≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare
(<1/10 000); not known (cannot be estimated from the available data). Within each frequency
grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage f4227843e307c6ade58940b825d50825bb381a83e03b959a982218ecae712c84 · Zeichen 1471–1861 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 33–34
HOS-115585 · Präparat HOS-094307
33
Table 6
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 755784fff26a9425b4fc0ad4e8dbc022c1416279bea0b9f533d48acb4b282ab8 · Zeichen 1917–1928 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 34
HOS-115586 · Präparat HOS-094307
Blood and lymphatic system disorders
Not known: Pancytopenia1, thrombocytopenia1, anaemia aggravated1,
neutropenia1
Immune system disorders
Not known: Hypersensitivity reactions (including anaphylactic reactions and
angioedema)1
Metabolism and nutrition disorders
Not known: Metabolic acidosis1
Psychiatric disorders
Uncommon: Anxiety, sleep disorder
Nervous system disorders
Common: Headache
Uncommon: Dizziness
Eye disorders
Uncommon: Cataract, maculopathy
Rare: Optic neuritis
Ear and labyrinth disorders
Uncommon: Deafness
Respiratory, thoracic and mediastinal disorders
Uncommon: Laryngeal pain
Gastrointestinal disorders
Common: Diarrhoea, constipation, vomiting, nausea, abdominal pain,
abdominal distension, dyspepsia
Uncommon: Gastrointestinal haemorrhage, gastric ulcer (including multiple
ulcers), duodenal ulcer, gastritis
Rare: Oesophagitis
Not known: Gastrointestinal perforation1, acute pancreatitis1
Hepatobiliary disorders
Common: Transaminases increased
Uncommon: Hepatitis, cholelithiasis
Not known: Hepatic failure1, 2
Skin and subcutaneous tissue disorders
Common: Rash, pruritus
Uncommon: Pigmentation disorder
Rare: Drug reaction with eosinophilia and systemic symptoms (DRESS)
Not known: Stevens-Johnson syndrome1, hypersensitivity vasculitis1, urticaria1,
erythema multiforme1, alopecia1, toxic epidermal necrolysis (TEN)1
Renal and urinary disorders
Very common: Blood creatinine increased
Common: Proteinuria
Uncommon: Renal tubular disorder2 (acquired Fanconi syndrome), glycosuria
Not known: Acute renal failure1, 2, tubulointerstitial nephritis1, nephrolithiasis1,
renal tubular necrosis1
General disorders and administration site conditions
Uncommon: Pyrexia, oedema, fatigue
1
Adverse reactions reported during post-marketing experience. These are derived from
spontaneous reports for which it is not always possible to reliably establish frequency or a
causal relationship to exposure to the medicinal product.
2
Severe forms associated with changes in consciousness in the context of hyperammonaemic
encephalopathy have been reported.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 925e8c517460be4330d42c90b9eed3b2d77c7a46c08659853b03f0b3b8099e99 · Zeichen 1932–4729 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 34–35
HOS-115587 · Präparat HOS-094307
34
Description of selected adverse reactions
Gallstones and related biliary disorders were reported in about 2% of patients. Elevations of liver
transaminases were reported as an adverse reaction in 2% of patients. Elevations of transaminases
greater than 10 times the upper limit of the normal range, suggestive of hepatitis, were uncommon
(0.3%). During post-marketing experience, hepatic failure, sometimes fatal, has been reported with
deferasirox (see section 4.4). There have been post-marketing reports of metabolic acidosis. The
majority of these patients had renal impairment, renal tubulopathy (Fanconi syndrome) or diarrhoea,
or conditions where acid-base imbalance is a known complication (see section 4.4). Cases of serious
acute pancreatitis were observed without documented underlying biliary conditions. As with other iron
chelator treatment, high-frequency hearing loss and lenticular opacities (early cataracts) have been
uncommonly observed in patients treated with deferasirox (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 474ad433802d3a1a85ce3144d15da68d197c130500f163a8f59dc8dc8bd7bc8d · Zeichen 4785–5801 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 35
HOS-115588 · Präparat HOS-094307
Creatinine clearance in transfusional iron overload
In a retrospective meta-analysis of 2 102 adult and paediatric beta-thalassaemia patients with
transfusional iron overload treated with deferasirox dispersible tablets in two randomised and four
open label studies of up to five years’ duration, a mean creatinine clearance decrease of 13.2% in adult
patients (95% CI: -14.4% to -12.1%; n=935) and 9.9% (95% CI: -11.1% to -8.6%; n=1 142) in
paediatric patients was observed during the first year of treatment. In 250 patients who were followed
for up to five years, no further decrease in mean creatinine clearance levels was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 5a97dbf5702e7bdc9f6e639cd5e6ba9650874f44e2f60c31d7d8ca034e692c8b · Zeichen 5803–6439 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 35
HOS-115589 · Präparat HOS-094307
Clinical study in patients with non-transfusion-dependent thalassaemia syndromes
In a 1-year study in patients with non-transfusion-dependent thalassaemia syndromes and iron
overload (dispersible tablets at a dose of 10 mg/kg/day), diarrhoea (9.1%), rash (9.1%), and nausea
(7.3%) were the most frequent study drug-related adverse events. Abnormal serum creatinine and
creatinine clearance values were reported in 5.5% and 1.8% of patients, respectively. Elevations of
liver transaminases greater than 2 times the baseline and 5 times the upper limit of normal were
reported in 1.8% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 383be065a8d9afd8c4993904e06322e3af97fdf4985dd74fff1d36adddde8b8b · Zeichen 6441–7036 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 35
HOS-115590 · Präparat HOS-094307
Paediatric population
In three clinical studies, growth and sexual development of paediatric patients treated with deferasirox
for up to 5 years were not affected (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage c2dec7628871ee0855c50e319162a80b45ce2110656a55a48c2373d885021787 · Zeichen 7038–7219 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 35
HOS-115591 · Präparat HOS-094307
Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years than in older patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage 9bd3742414ca9dead248728436cd50a01deb6dabe7981bd2bee444be03d01f16 · Zeichen 7221–7321 im Abschnitt
Nebenwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.8 · PDF-Seite 35
HOS-115592 · Präparat HOS-094307
Renal tubulopathy has been mainly reported in children and adolescents with beta-thalassaemia treated
with deferasirox. In post-marketing reports, a high proportion of cases of metabolic acidosis occurred
in children in the context of Fanconi syndrome.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage b624bee1a82c9e88370024b6842449a21bb2ee74c789ceca877fb11fc22dc6ca · Zeichen 7323–7575 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.